<SEC-DOCUMENT>0001209191-13-043004.txt : 20130904
<SEC-HEADER>0001209191-13-043004.hdr.sgml : 20130904
<ACCEPTANCE-DATETIME>20130904173047
ACCESSION NUMBER:		0001209191-13-043004
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20130903
FILED AS OF DATE:		20130904
DATE AS OF CHANGE:		20130904

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARCA biopharma, Inc.
		CENTRAL INDEX KEY:			0000907654
		STANDARD INDUSTRIAL CLASSIFICATION:	IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
		IRS NUMBER:				363855489
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 430
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021
		BUSINESS PHONE:		720-940-2200

	MAIL ADDRESS:	
		STREET 1:		8001 ARISTA PLACE
		STREET 2:		SUITE 430
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	NUVELO INC
		DATE OF NAME CHANGE:	20030203

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	HYSEQ INC
		DATE OF NAME CHANGE:	19970610

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			CONWAY ROBERT E
		CENTRAL INDEX KEY:			0001184334

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-22873
		FILM NUMBER:		131078708

	MAIL ADDRESS:	
		STREET 1:		C/O ARCA BIOPHARMA, INC
		STREET 2:		8001 ARISTA PLACE, STE 430
		CITY:			BROOMFIELD
		STATE:			CO
		ZIP:			80021

	FORMER NAME:	
		FORMER CONFORMED NAME:	CONWAY ROBERT
		DATE OF NAME CHANGE:	20020829
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>c592958_3x1.xml
<DESCRIPTION>MAIN DOCUMENT DESCRIPTION
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2013-09-03</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0000907654</issuerCik>
        <issuerName>ARCA biopharma, Inc.</issuerName>
        <issuerTradingSymbol>ABIO</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001184334</rptOwnerCik>
            <rptOwnerName>CONWAY ROBERT E</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ARCA BIOPHARMA, INC.</rptOwnerStreet1>
            <rptOwnerStreet2>8001 ARISTA PLACE, SUITE 430</rptOwnerStreet2>
            <rptOwnerCity>BROOMFIELD</rptOwnerCity>
            <rptOwnerState>CO</rptOwnerState>
            <rptOwnerZipCode>80021</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>1</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>0</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>0</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Option to Purchase Common Stock</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>1.33</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2023-09-03</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>1250</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The options vest in equal monthly installments over a three (3) year period, beginning on the grant date of September 3, 2013.  If the Reporting Person's service as a director of the Issuer terminates in connection with or at any time following a change in control (for whatever reason), then any unexpired options that remain unvested shall become fully vested.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Patrick M. Wheeler, Attorney-in-Fact</signatureName>
        <signatureDate>2013-09-04</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>c592958_24.htm
<DESCRIPTION>POWER OF ATTORNEY
<TEXT>
<html>
<head>
     <title>Exhibit 24</title>
</head>
<body>
<PRE>

                                                                      Exhibit 24

                               POWER OF ATTORNEY

      Know all by these presents, that the undersigned hereby constitutes and
appoints each of Christopher D. Ozeroff, Patrick M. Wheeler, Brian Selby and
Brent D. Fassett, signing individually, the undersigned's true and lawful
attorneys-in fact and agents to:

            (1) execute for and on behalf of the undersigned, an officer,
      director or holder of 10% of more of a registered class of securities of
      ARCA biopharma, Inc. (the "Company"), Forms 3, 4 and 5 in accordance with
      Section 16(a) of the Securities Exchange Act of 1934, as amended (the
      "Exchange Act") and the rules thereunder;

            (2) do and perform any and all acts for and on behalf of the
      undersigned that may be necessary or desirable to complete and execute
      such Form 3, 4 or 5, complete and execute any amendment or amendments
      thereto, and timely file such forms or amendments with the United States
      Securities and Exchange Commission and any stock exchange or similar
      authority; and

            (3) take any other action of any nature whatsoever in connection
      with the foregoing which, in the opinion of such attorney-in-fact, may be
      of benefit, in the best interest of, or legally required by, the
      undersigned, it being understood that the documents executed by such
      attorney-in-fact on behalf of the undersigned pursuant to this Power of
      Attorney shall be in such form and shall contain such terms and conditions
      as such attorney-in-fact may approve in such attorney-in-fact's
      discretion.

      The undersigned hereby grants to each such attorney-in-fact full power and
authority to do and perform any and every act and thing whatsoever requisite,
necessary, or proper to be done in the exercise of any of the rights and powers
herein granted, as fully to all intents and purposes as the undersigned might or
could do if personally present, with full power of substitution or revocation,
hereby ratifying and confirming all that such attorney-in-fact, or such
attorney-in-fact's substitute or substitutes, shall lawfully do or cause to be
done by virtue of this power of attorney and the rights and powers herein
granted.  The undersigned acknowledges that the foregoing attorneys-in-fact, in
serving in such capacity at the request of the undersigned, are not assuming,
nor is the Company assuming, any of the undersigned's responsibilities to comply
with Section 16 of the Exchange Act.

      This Power of Attorney shall remain in full force and effect until the
earliest to occur of (a) the undersigned is no longer required to file Forms 3,
4 and 5 with respect to the undersigned's holdings of and transactions in
securities issued by the Company, (b) revocation by the undersigned in a signed
writing delivered to the foregoing attorneys-in-fact or (c) as to any attorney-
in-fact individually, until such attorney-in-fact shall no longer be employed by
the Company or Cooley Godward Kronish LLP, as applicable.

      IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to
be executed as of this 28th day of August, 2013.


                                                /s/ Robert E. Conway
                                                --------------------------------
                                                Robert E. Conway


</PRE>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
